Loading clinical trials...
Loading clinical trials...
Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab (Erbitux) and Erlotinib (Tarceva) in Patients With Chemotherapy-refractory Colorectal Cancer
Conditions
Interventions
Cetuximab
Erlotinib
Locations
4
Australia
Royal North Shore Hospital
Sydney, New South Wales, Australia
Queen Elizabeth Hospital
Adelaide, South Australia, Australia
Ballarat Base Hospital
Ballarat, Victoria, Australia
Austin Health
Melbourne, Victoria, Australia
Start Date
October 1, 2008
Primary Completion Date
January 1, 2010
Completion Date
February 1, 2011
Last Updated
November 30, 2010
NCT04657068
NCT06625775
NCT06607458
NCT06820463
NCT07361003
NCT06792695
Lead Sponsor
Austin Health
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions